Ulcerative Colitis | Treatment Algorithms | Claims Data Analysis | US | 2014

As more biologics are approved to treat ulcerative colitis (UC), it is important to analyze the changes in gastroenterologists’ prescribing behaviors. This report uses national patient-level claims data to explore the use of key therapies in newly diagnosed UC patients with a quantitative analysis of treatment patterns and share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. Among recently treated patients, we quantify a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliance by brand.

launch Related Market Assessment Reports